
Marksans Q2 FY27: consolidated PAT +45% YoY to ₹143.5 Cr, margins ease off Q1's record
Marksans Pharma's consolidated revenue for the September 2026 quarter rose 30.5% YoY to ₹940.17 Cr (+11.8% QoQ), with consolidated PAT up 44.8% YoY to ₹143.53 Cr (₹141.31 Cr attributable to owners; basic EPS ₹3.12 vs ₹2.17 a year ago). Sequentially, PAT eased 10.0% QoQ against Q1 FY27's record ₹159.41 Cr, and OPM moderated to 22.81% from Q1's 25.34% peak — still up from 20.06% a year ago, so the YoY growth story is intact; this is a sequential cool-off after an unusually strong June quarter, not a reversal. No exceptional items were reported in either the current or comparative periods, so the growth is on a like-for-like basis. Gross margin held near 58.5%, down only marginally from Q1's 59.1% and still well above the 55-56% band management guided as the 'normalized' level for the year — that normalization has not materially shown up yet. NPM (PAT/total income) came in at 14.98%, up from 13.36% YoY but down from Q1's 18.40%, tracking the OPM move. Total expenses were ₹764.82 Cr against total income of ₹958.32 Cr for the quarter. Against management's own FY27 guidance from the August 20, 2026 concall — 15-20% revenue growth and a 20-21% sustainable / 21-22% year-end EBITDA margin band — this quarter's 30.5% YoY revenue growth and 22.81% OPM both run ahead of plan even with the QoQ dip. Gross margin normalization to 55-56% is the one guided metric not yet realized and is now the gap to watch. No Street estimates specific to this quarter were found in a search (the result was announced today), so vsStreet is unknown; management issued no separate press release with this filing beyond the procedural board-outcome letter, so there is no company framing to reconcile against. During the half year the company completed two bolt-on European acquisitions — QliniQ B.V. in the Netherlands (EUR 7.5 million, effective April 1, 2026) and ABCnow GmbH in Germany (EUR 1.1 million, effective July 1, 2026) — consistent with management's stated Europe push (full-year Europe revenue target of ₹180 Cr cited in the prior concall). Standalone (India entity) scale remains far smaller — PBT of just ₹13.71 Cr for the quarter — underscoring that most group profitability now sits in the US/UK/Europe subsidiary structure visible only at the consolidated level.
Key Highlights
- Consolidated revenue ₹940.17 Cr, +30.5% YoY / +11.8% QoQ; consolidated PAT ₹143.53 Cr, +44.8% YoY but -10.0% QoQ off Q1 FY27's record ₹159.41 Cr
- OPM 22.81% (vs 20.06% YoY, expansion) but down from Q1's record 25.34%; NPM (PAT/total income) 14.98% vs 13.36% YoY, down from Q1's 18.40%
- Gross margin ~58.5%, still well above the 55-56% level management guided as 'normalized' from Q1's 59.1% — normalization not yet visible
- FY27 guidance of 15-20% revenue growth and 20-22% EBITDA margin band — Q2's 30.5% growth and 22.81% OPM both run ahead of plan
- Two bolt-on European acquisitions completed this half: QliniQ B.V., Netherlands (EUR 7.5M, w.e.f. Apr 1, 2026) and ABCnow GmbH, Germany (EUR 1.1M, w.e.f. Jul 1, 2026)
- Basic EPS ₹3.12 (vs ₹2.17 YoY, ₹3.47 in Q1); PAT attributable to owners ₹141.31 Cr of total ₹143.53 Cr, non-controlling interests ~₹2.2 Cr
- Standalone entity PBT just ₹13.71 Cr for the quarter — bulk of group profit sits in the consolidated US/UK/Europe subsidiary structure
Price Impact
More from MARKSANS